Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
Xenon reported positive Phase 1 data for XEN1701 and XEN1120, supporting advancement of both non-opioid pain candidates into Phase 2 proof-of-concept acute pain studies expected to begin in H1 2027. XEN1701 achieved more than 75% Na(V)1.7 receptor occupancy in both peripheral and central nervous system with twice-daily dosing and showed no consistent pattern of cardiovascular effects, a common failure point for prior Na(V)1.7 programs.
Key figures
- Drug Name
- XEN1701 and XEN1120
- Phase Of Trial
- Phase 1 (advancing to Phase 2)
- Phase2 initiation
- H1 2027
- Nav1 7 receptor occupancy
- >75% in peripheral and central nervous system with BID dosing
- Xen1120 phase1 enrollment
- n=54 XEN1120 vs n=18 placebo
- Xen1701 phase1 enrollment
- n=76 XEN1701 vs n=22 placebo
- Preclinical pain reduction
- ~85-100% reduction in capsaicin-evoked heat pain at two highest XPC-4 doses
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.